Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffinic oil - emulsifiable suspension - paraffinic oil petroleum derivative-oil active 821.0 g/l - insecticide - avocado | banana | citrus | custard apple | grape | kiwi fruit | mango | pome fruit | stone fruit | weed control | apple | apric - black scale | black spot - colletotrichum acutatum | bryobia mite | bryobia mite - eggs | carmine mite | cercospora leaf spot | citrus leafminer | cordana leaf spot | european red mite (erm) - eggs | grapevine scale | leaf speckle on banana | oystershell scale | pinkwax scale | powdery mildew | red scale | san jose' scale | scale insects | soft brown scale | tank mixing | white wax scale | additive | agricultural chemical | anthracnose | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | herbicide | minimise antagonism | quadraspidiotus perniciosus | red spider mite | spider mite | spray tank | two-spotted mite | two-spotted spider mite

Ավստրալիա - անգլերեն - Department of Health (Therapeutic Goods Administration)

medtronic australasia pty ltd - 46425 - bone matrix implant, animal-derived, bioabsorbable - mastergraft? putty is supplied as a sterile, dry, solid, construct that is hydrated for single patient use and is a mouldable form of bone void filler. mastergraft? products are biocompatible, osteoconductive, porous implants that allows for bony in growth across the graft site while resorbing at a rate consistent with bone healing. mastergraft? putty is intended to help fill voids or gaps in bone, which may be surgically created osseous defects, or osseous defects caused by traumatic injury to the bone. mastergraft? putty provides a bone void filler that is resorbed and is replaced with bone during the natural healing process. the putty when combined with either autogenous bone marrow, and/or sterile water, and/or autograft is indicated as a bone void filler for bony voids or gaps that are not intrinsic to the stability of the bony structure. additionally, mastergraft putty can be used with autograft as a bone extender. specific indications for use include oral/maxillofacial augmentation or reconstruction.

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffin oil - emulsion - paraffin oil petroleum derivative-oil active 19.46 g/l - insecticide - apple | apricot | citrus | grape | peach | pear | plum | pome fruit | rose | stone fruit | apple | apricot | cherry | delicious - aphid | black scale | citrus leafminer | grapevine scale | mealy bug | oystershell scale | pinkwax scale | red scale | san jose' scale | scale | soft brown scale | spider mite | white wax scale | whitefly | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | mealybug | quadraspidiotus perniciosus

Ավստրալիա - անգլերեն - APVMA (Australian Pesticides and Veterinary Medicines Authority)

sbc asia pacific pty ltd - paraffin oil - emulsifiable concentrate - paraffin oil petroleum derivative-oil active 811.0 g/l - insecticide - citrus | grape | ornamental (see label) | pome fruit | rose | stone fruit | apple | apricot | cherry | grapefruit | grapevine | - aphid | black scale | citrus leafminer | grapevine scale | mealy bug | oystershell scale | pinkwax scale | red scale | san jose' scale | scale | soft brown scale | spider mite | white wax scale | whitefly | citrus red scale | diaspidiotus ostreaeformis | diaspidiotus perniciosus | mealybug | quadraspidiotus perniciosus

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

xorix sdn bhd - salicylic acid -

Մալայզիա - անգլերեն - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

tiger balm (m) sdn bhd - cajuput oil; clove oil; menthol; camphor -

Հարավաֆրիկյան Հանրապետություն - անգլերեն - South African Health Products Regulatory Authority (SAHPRA)

ceva animal health (pty) ltd - injection - see ingredients - each vial contains tiludronic acid a 50.0 mg - c 030101. steroidals

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

janssen pharmaceuticals, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancrelipase lipase 4200 [usp'u] - pancreaze (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. none. teratogenic effects pregnancy category c: animal reproduction studies have not been conducted with pancrelipase. it is not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. pancreaze should be given to a pregnant woman only if clearly needed. the risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a pregnant woman with exocrine pancreatic insufficiency. adequate caloric intake during pregnancy is important for normal maternal weight gain and fetal growth. reduced maternal weight gain and malnutrition can be associated with adverse pregnancy outcomes. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when pancreaze is administered to a nursing

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

abbvie inc. - pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e), pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50) - pancrelipase amylase 30000 [usp'u] - creon® is indicated for the treatment of exocrine pancreatic insufficiency in adult and pediatric patients. none. risk summary published data from case reports with pancrelipase use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. pancrelipase is minimally absorbed systematically; therefore, maternal use is not expected to result in fetal exposure to the drug. animal reproduction studies have not been conducted with pancrelipase. the background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. risk summary there are no data on the presence of pancrelipase in either human or animal milk, the effects on the breastfed infant or the effects on milk production. pancrelipase is minimally absorbed systemically following oral administration; therefore, maternal use is not expected to result in clinically relevant exposure of breastfed infants to the drug. the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for creon and any potential adverse effects on the breastfed infant from creon or from the underlying maternal condition. the safety and effectiveness of creon for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients. use of creon for this indication is supported by two adequate and well-controlled trials in adult and pediatric patients 12 years and older (study 1) and in pediatric patients 7 to 11 years of age (study 2) along with supportive data from an open-label, single-arm, study in 18 pediatric patients 4 months to six years of age (study 3). all three study populations consisted of patients with exocrine pancreatic insufficiency due to cystic fibrosis. the safety in pediatric patients 7 years of age and older in studies 1 and 2 were similar to that observed adult patients [see adverse reactions ( 6.1 ) and clinical studies ( 14 )] . in study 3, patients received their usual pancreatic enzyme replacement therapy (mean dose of 7,000 lipase units/kg/day for a mean duration of 18.2 days) followed by creon (mean dose of 7,500 lipase units/kg/day for a mean duration of 12.6 days). the mean daily fat intake was 48 grams during treatment with usual pancreatic enzyme replacement therapy and 47 grams during treatment with creon. adverse reactions that occurred in patients during treatment with creon in study 3 were vomiting, irritability, and decreased appetite [see adverse reactions ( 6.1 )] . dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. if there is a history of fibrosing colonopathy, monitor patients during treatment with creon because some patients may be at risk of progressing to stricture formation. do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation [see dosage and administration ( 2.2 ) and warnings and precautions ( 5.1 )] . crushing or chewing creon capsules or mixing the capsule contents in foods having a ph greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see dosage and administration ( 2.3 ) and warnings and precautions ( 5.2 ) ] . clinical studies of creon did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently from younger patients. other reported clinical experience has not identified differences in responses between patients aged 65 years and over and younger adult patients.

Ամերիկայի Միացյալ Նահանգներ - անգլերեն - NLM (National Library of Medicine)

allergan, inc. - pancrelipase lipase (unii: 8myc33932o) (pancrelipase lipase - unii:8myc33932o), pancrelipase protease (unii: 3560d81v50) (pancrelipase protease - unii:3560d81v50), pancrelipase amylase (unii: yoj58o116e) (pancrelipase amylase - unii:yoj58o116e) - pancrelipase lipase 3000 [usp'u] - zenpep® (pancrelipase) is indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis or other conditions. none. teratogenic effects pregnancy category c: animal reproduction studies have not been conducted with pancrelipase. it is also not known whether pancrelipase can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. zenpep should be given to a pregnant woman only if clearly needed. the risk and benefit of pancrelipase should be considered in the context of the need to provide adequate nutritional support to a pregnant woman with exocrine pancreatic insufficiency. adequate caloric intake during pregnancy is important for normal maternal weight gain and fetal growth. reduced maternal weight gain and malnutrition can be associated with adverse pregnancy outcomes. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, caution should be exercised when zenpep is administered to a nursing